Polaris AI Pharma Q1 net profit surges 271%, conducts share buyback and CB issuance
Q1 2026 revenue 13.7B KRW (vs 12.7B), operating profit 0.6B (vs 0.7B) declined, but net profit surged 271% to 3.7B due to 4.3B fair value gain on financial assets.
EPS 275 KRW (vs 74).
Cancelled 218,257 treasury shares (approx. 1.9B) on March 31, 2026, enhancing shareholder value.
Issued 10B KRW unsecured private CB on March 26, 2026 (conversion price 9,106 won, maturity 2030), convertible into 1,098,177 shares.
Debt ratio improved to 40.53% from 44.14%.
Major shareholder (Polaris Office and affiliates) holds 29.50%.
Expanding into AI-driven drug development and healthcare businesses.